Investment
Features
FeesSafety
Academy
More
Pluang+

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

Analyst Insights
14 Aug 2026
Alex Lavoie
View Source
Bullish
pluang ai news

Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew 55% and assets 40% year-over-year, supported by rising cash flows. Despite risks from high commercial real estate loan concentration and declining capital ratios, the stock's forward P/E of 9.10 remains attractive to investors.

More News

Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the pric...

Company Fundamentals
Bullish
51 minutes ago
Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.

Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.

Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...

Market News
Bullish
56 minutes ago
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
2 hours ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
2 hours ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App